BR112012015951A2 - 4 azido-nucleosídeos como compostos anti-hcv - Google Patents
4 azido-nucleosídeos como compostos anti-hcvInfo
- Publication number
- BR112012015951A2 BR112012015951A2 BR112012015951A BR112012015951A BR112012015951A2 BR 112012015951 A2 BR112012015951 A2 BR 112012015951A2 BR 112012015951 A BR112012015951 A BR 112012015951A BR 112012015951 A BR112012015951 A BR 112012015951A BR 112012015951 A2 BR112012015951 A2 BR 112012015951A2
- Authority
- BR
- Brazil
- Prior art keywords
- hcv
- compounds
- hcv compounds
- nucleosides
- azido
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29922910P | 2010-01-28 | 2010-01-28 | |
PCT/EP2011/050971 WO2011092158A1 (en) | 2010-01-28 | 2011-01-25 | 4 ' - azido - nucleosides as anti - hcv compunds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012015951A2 true BR112012015951A2 (pt) | 2018-10-16 |
Family
ID=43587111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012015951A BR112012015951A2 (pt) | 2010-01-28 | 2011-01-25 | 4 azido-nucleosídeos como compostos anti-hcv |
Country Status (16)
Country | Link |
---|---|
US (1) | US8236779B2 (pt) |
EP (1) | EP2528930B1 (pt) |
JP (1) | JP5675849B2 (pt) |
KR (1) | KR101384389B1 (pt) |
CN (1) | CN102725303B (pt) |
BR (1) | BR112012015951A2 (pt) |
CA (1) | CA2784330C (pt) |
DK (1) | DK2528930T3 (pt) |
ES (1) | ES2437933T3 (pt) |
HK (1) | HK1176938A1 (pt) |
MX (1) | MX337050B (pt) |
PL (1) | PL2528930T3 (pt) |
PT (1) | PT2528930E (pt) |
RU (1) | RU2556991C2 (pt) |
TW (1) | TW201141488A (pt) |
WO (1) | WO2011092158A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012040124A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物 |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
EP2852603B1 (en) | 2012-05-22 | 2021-05-12 | Idenix Pharmaceuticals LLC | D-amino acid compounds for liver disease |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
HUE029038T2 (en) | 2012-05-25 | 2017-01-30 | Janssen Sciences Ireland Uc | Uracil spirooxetan nucleosides |
EP2900682A1 (en) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
CN111848711A (zh) | 2012-10-08 | 2020-10-30 | 埃迪尼克斯医药有限责任公司 | 用于hcv感染的2′-氯核苷类似物 |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US20140271547A1 (en) | 2013-03-13 | 2014-09-18 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
WO2015189386A1 (en) * | 2014-06-13 | 2015-12-17 | Teva Pharmaceuticals International Gmbh | Composition with a high drug load of sofosbuvir |
HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
WO2016204531A1 (ko) * | 2015-06-16 | 2016-12-22 | 엘지전자(주) | 블록 경계에 따라 적응적으로 필터링을 수행하는 방법 및 장치 |
JP6804790B1 (ja) * | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | N4−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
CN113880903B (zh) * | 2021-09-23 | 2024-07-02 | 厦门蔚嘉制药有限公司 | 莫那比拉韦的制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100457118C (zh) * | 2000-04-13 | 2009-02-04 | 法玛塞特有限公司 | 用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物 |
CN1646141B (zh) * | 2000-10-18 | 2014-06-25 | 吉利德制药有限责任公司 | 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物 |
EP1355916B1 (en) * | 2001-01-22 | 2007-01-10 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
NZ536123A (en) * | 2002-05-06 | 2006-09-29 | Genelabs Tech Inc | Nucleoside derivatives for treating hepatitis C virus infection |
CN100351264C (zh) * | 2002-11-19 | 2007-11-28 | 霍夫曼-拉罗奇有限公司 | 抗病毒核苷衍生物 |
TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
PL1962808T3 (pl) * | 2005-12-14 | 2011-03-31 | Hoffmann La Roche | Preparat proleku przeciw HCV |
US20090318380A1 (en) * | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
AR069740A1 (es) * | 2007-11-29 | 2010-02-17 | Metabasis Therapeutics Inc | Compuestos nucleosidos antivirales |
-
2011
- 2011-01-25 DK DK11701107.2T patent/DK2528930T3/da active
- 2011-01-25 PT PT117011072T patent/PT2528930E/pt unknown
- 2011-01-25 KR KR1020127022217A patent/KR101384389B1/ko not_active IP Right Cessation
- 2011-01-25 WO PCT/EP2011/050971 patent/WO2011092158A1/en active Application Filing
- 2011-01-25 EP EP11701107.2A patent/EP2528930B1/en not_active Not-in-force
- 2011-01-25 CA CA2784330A patent/CA2784330C/en not_active Expired - Fee Related
- 2011-01-25 PL PL11701107T patent/PL2528930T3/pl unknown
- 2011-01-25 CN CN201180007367.0A patent/CN102725303B/zh not_active Expired - Fee Related
- 2011-01-25 ES ES11701107.2T patent/ES2437933T3/es active Active
- 2011-01-25 BR BR112012015951A patent/BR112012015951A2/pt active Search and Examination
- 2011-01-25 MX MX2012008443A patent/MX337050B/es active IP Right Grant
- 2011-01-25 RU RU2012136379/04A patent/RU2556991C2/ru not_active IP Right Cessation
- 2011-01-25 TW TW100102705A patent/TW201141488A/zh unknown
- 2011-01-25 JP JP2012550415A patent/JP5675849B2/ja not_active Expired - Fee Related
- 2011-01-26 US US13/014,022 patent/US8236779B2/en not_active Expired - Fee Related
-
2013
- 2013-04-09 HK HK13104289.7A patent/HK1176938A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2784330C (en) | 2018-02-13 |
MX2012008443A (es) | 2012-08-15 |
PT2528930E (pt) | 2013-11-26 |
KR20120110177A (ko) | 2012-10-09 |
TW201141488A (en) | 2011-12-01 |
MX337050B (es) | 2016-02-10 |
RU2556991C2 (ru) | 2015-07-20 |
PL2528930T3 (pl) | 2014-03-31 |
CN102725303B (zh) | 2015-05-27 |
ES2437933T3 (es) | 2014-01-15 |
RU2012136379A (ru) | 2014-03-10 |
KR101384389B1 (ko) | 2014-04-10 |
US20110150829A1 (en) | 2011-06-23 |
CA2784330A1 (en) | 2011-08-04 |
EP2528930A1 (en) | 2012-12-05 |
WO2011092158A1 (en) | 2011-08-04 |
EP2528930B1 (en) | 2013-10-30 |
JP5675849B2 (ja) | 2015-02-25 |
HK1176938A1 (en) | 2013-08-09 |
DK2528930T3 (da) | 2013-11-11 |
JP2013518076A (ja) | 2013-05-20 |
US8236779B2 (en) | 2012-08-07 |
CN102725303A (zh) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012015951A2 (pt) | 4 azido-nucleosídeos como compostos anti-hcv | |
MX2012003170A (es) | Compuestos heterociclicos antivirales. | |
MX2010004623A (es) | Compuestos heterociclicos antiviricos. | |
CR10136A (es) | Nucleósidos antivirales | |
TW200720285A (en) | Nucleoside compounds for treating viral infections | |
EA200901101A1 (ru) | Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс | |
EA201491179A1 (ru) | 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с | |
EA201791776A1 (ru) | Замещенные циклофаны для использования при лечении инфекции вгс | |
CO6561788A2 (es) | Inhibidores del virus de la hepatitis c | |
CR20110605A (es) | Compuestos heterocíclicos antivirales | |
MX2011006631A (es) | Inhibidores de proteasa ns3 del virus hcv. | |
DK2209789T3 (da) | Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere | |
EA201000948A1 (ru) | Ингибиторы вирусной полимеразы | |
BR112012014299A2 (pt) | composto de antivírus heterocíclicos | |
MX2011012541A (es) | Compuestos heterociclicos antivirales. | |
EA201391717A1 (ru) | Ингибиторы вируса гепатита с | |
BRPI1016167A2 (pt) | compostos heterocíclicos antivirais. | |
AR057641A1 (es) | Compuestos 5- nitro - nucleosidos para tratar infecciones virales | |
BRPI0716060A2 (pt) | inibidores de polimerase viral. | |
MX2011012240A (es) | Compuestos heterociclicos antivirales. | |
MX2013004464A (es) | Inhibidores de polimerasa viral. | |
BR112013000245A2 (pt) | compostos antivirais heterocíclicos | |
BR112012012085A2 (pt) | compostos antivirais heterocíclicos | |
MX2012002958A (es) | Compuestos antivirales heterociclicos. | |
ATE531373T1 (de) | Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25A | Requested transfer of rights approved |
Owner name: RIBOSCIENCE LLC (US) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2551 DE 26-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |